Graduate School of Medicine/Faculty of Medicine, Osaka University and Astellas establish joint research chair for R&D on next-generation cell therapyJoint Research Agreement • February 2nd, 2015
Contract Type FiledFebruary 2nd, 2015Tokyo, February 2, 2015 - The National University Corporation Osaka University ("Osaka University"; Administrative campus located in Suita-city, Osaka, Japan; President, Toshio Hirano) and Astellas Pharma Inc. ("Astellas"; TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) have entered into an agreement to establish a joint research chair* with a view developing fundamental technologies for next-generation cell therapies and bringing those technologies into practical use. Under the agreement, the joint research chair of “Department of Translational Cell Therapy (Organizing Professor: Professor Yoshiki Sawa, Cardiovascular Surgery, Department of Surgery)” has been established within the Graduate School of Medicine/Faculty of Medicine, Osaka University and will be tasked with developing the new technology platforms required to advance practical use of cell therapies, which are expected to be the next-generation therapies. The department will operate a laboratory facilit